At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 08 Jul 2008 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
- 18 Jun 1999 New profile
- 18 Jun 1999 Preclinical development for Reperfusion injury in USA (Unknown route)